ATE495193T1 - Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist - Google Patents
Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt istInfo
- Publication number
- ATE495193T1 ATE495193T1 AT02799075T AT02799075T ATE495193T1 AT E495193 T1 ATE495193 T1 AT E495193T1 AT 02799075 T AT02799075 T AT 02799075T AT 02799075 T AT02799075 T AT 02799075T AT E495193 T1 ATE495193 T1 AT E495193T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnostics
- research
- treatment
- cell death
- diseases involving
- Prior art date
Links
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 title abstract 2
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000030833 cell death Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01830834A EP1323733A1 (de) | 2001-12-28 | 2001-12-28 | BAG3-Nukleotid- und Proteinsequenzen zur Nutzung in Forschung, Diagnose und der Behandlung von Krankheiten, an denen Zelltod beteiligt ist |
| PCT/EP2002/014802 WO2003055908A2 (en) | 2001-12-28 | 2002-12-30 | Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE495193T1 true ATE495193T1 (de) | 2011-01-15 |
Family
ID=8184857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02799075T ATE495193T1 (de) | 2001-12-28 | 2002-12-30 | Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7537760B2 (de) |
| EP (2) | EP1323733A1 (de) |
| AT (1) | ATE495193T1 (de) |
| AU (1) | AU2002364302A1 (de) |
| CA (1) | CA2471924C (de) |
| CY (1) | CY1111371T1 (de) |
| DE (1) | DE60238945D1 (de) |
| DK (1) | DK1465927T3 (de) |
| ES (1) | ES2359396T3 (de) |
| SI (1) | SI1465927T1 (de) |
| WO (1) | WO2003055908A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1397083B1 (it) * | 2009-12-04 | 2012-12-28 | Biouniversa Srl | Marcatore biochimico serico |
| KR101436684B1 (ko) | 2012-03-09 | 2014-09-01 | 가톨릭대학교 산학협력단 | 저산소성 허혈 예방 또는 치료용 조성물 |
| ITMI20130403A1 (it) * | 2013-03-18 | 2014-09-19 | Biouniversa Srl | Anticorpi anti-bag3 per uso terapeutico |
| EP2676966A1 (de) * | 2012-06-19 | 2013-12-25 | Biouniversa S.r.l. | BAG3 als biochemisches Serum und Gewebemarker |
| ITMI20131351A1 (it) * | 2013-08-07 | 2015-02-08 | Biouniversa Srl | Molecole leganti il recettore di bag3 per uso terapeutico. |
| CA2975258A1 (en) * | 2014-01-31 | 2015-08-06 | Temple University Of The Commonwealth System Of Higher Education | Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction |
| ITUB20155097A1 (it) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
| IT201600069391A1 (it) * | 2016-07-04 | 2016-10-04 | Univ Degli Studi Di Salerno | Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare |
| IT201600111877A1 (it) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
| CA3107625A1 (en) * | 2017-07-28 | 2019-01-31 | Biouniversa S.R.L. | Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases |
| WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
| IL312509A (en) * | 2021-10-22 | 2024-07-01 | Univ Loyola Chicago | BAG3 methods and uses for treating inflammation |
| EP4518882A1 (de) * | 2022-05-03 | 2025-03-12 | Temple University of the Commonwealth System of Higher Education | Bag3 und kontrolle der proteinqualität im gehirn |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5652223A (en) * | 1994-03-14 | 1997-07-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA encoding CAI resistance proteins and uses thereof |
| JPH10327872A (ja) * | 1997-05-30 | 1998-12-15 | Otsuka Pharmaceut Co Ltd | Ｂｃｌ−２相互作用蛋白遺伝子ｂｉｓ |
| US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
| JP2002524068A (ja) * | 1998-09-09 | 2002-08-06 | ザ バーナム インスティチュート | 新規なｂａｇタンパク質およびそれらをコードする核酸分子 |
-
2001
- 2001-12-28 EP EP01830834A patent/EP1323733A1/de not_active Withdrawn
-
2002
- 2002-12-30 US US10/500,665 patent/US7537760B2/en not_active Expired - Lifetime
- 2002-12-30 DE DE60238945T patent/DE60238945D1/de not_active Expired - Lifetime
- 2002-12-30 ES ES02799075T patent/ES2359396T3/es not_active Expired - Lifetime
- 2002-12-30 AU AU2002364302A patent/AU2002364302A1/en not_active Abandoned
- 2002-12-30 WO PCT/EP2002/014802 patent/WO2003055908A2/en not_active Application Discontinuation
- 2002-12-30 DK DK02799075.3T patent/DK1465927T3/da active
- 2002-12-30 EP EP02799075A patent/EP1465927B1/de not_active Expired - Lifetime
- 2002-12-30 AT AT02799075T patent/ATE495193T1/de active
- 2002-12-30 CA CA2471924A patent/CA2471924C/en not_active Expired - Lifetime
- 2002-12-30 SI SI200230936T patent/SI1465927T1/sl unknown
-
2009
- 2009-05-21 US US12/454,772 patent/US20090306192A1/en not_active Abandoned
-
2011
- 2011-04-05 CY CY20111100354T patent/CY1111371T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1111371T1 (el) | 2015-08-05 |
| EP1465927B1 (de) | 2011-01-12 |
| SI1465927T1 (sl) | 2011-05-31 |
| CA2471924C (en) | 2013-11-12 |
| US20090306192A1 (en) | 2009-12-10 |
| EP1465927A2 (de) | 2004-10-13 |
| US20050176660A1 (en) | 2005-08-11 |
| DK1465927T3 (da) | 2011-04-18 |
| WO2003055908A2 (en) | 2003-07-10 |
| AU2002364302A8 (en) | 2003-07-15 |
| DE60238945D1 (de) | 2011-02-24 |
| EP1323733A1 (de) | 2003-07-02 |
| US7537760B2 (en) | 2009-05-26 |
| AU2002364302A1 (en) | 2003-07-15 |
| CA2471924A1 (en) | 2003-07-10 |
| WO2003055908A3 (en) | 2004-03-11 |
| ES2359396T3 (es) | 2011-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111371T1 (el) | Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο | |
| AU7494701A (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| DK1409544T3 (da) | Humane DR4-antistoffer og anvendelser deraf | |
| ATE531729T1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
| DE602005019064D1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| DE60042066D1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE411805T1 (de) | Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen | |
| NO903059L (no) | Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse. | |
| DK1450799T5 (da) | Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| DE69815703D1 (de) | Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen | |
| ATE350385T1 (de) | Neue aryl fructose-1,6-bisphosphatase inhibitoren | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| ATE128128T1 (de) | Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one. | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| ATE311476T1 (de) | Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
| NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
| ATE435284T1 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
| DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE364180T1 (de) | Screeningverfahren mit bnpi und dnpi | |
| DE60224778D1 (de) | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1465927 Country of ref document: EP |